Invetech is extending its offering beyond custom cell and gene therapy manufacturing solutions and consulting services to include ready-to-run turnkey [1] systems to accelerate the development and commercialization of life-changing therapies.

Two decades ago, in the early days of cell therapeutics, our challenge was to help our clients unlock the biological potential from a lab into a level of technical feasibility at manufacturing production scale.

With the fast acceleration of the industry, the pressure on client resources and speed-to-market imperatives called for increasingly advanced technical design, engineering and manufacturing methods.

“With the rapid acceleration of cell and gene therapies, the industry is in need of highly effective, efficient and scalable technologies that can rapidly grow with the therapies’ development and commercial evolution,” said Andreas Knaack, Invetech’s President.

In advocating for these life-saving advances, we recognized more needed to be done to accelerate and enhance the development and manufacturing capability available to the cell therapy market — to make more therapies economically viable and accessible to more people.

Over the years, we have worked with hundreds of advanced scientists, clinicians, technicians and operations managers worldwide. Through our work, we have gained great insight into common user needs and challenges, design parameters, technical specifications and production factors.

Knaack said, “As an invested healthcare innovation partner with almost 20 years of history in automating the production of cell and gene therapies, our new offering of ready-to-run turnkey cell therapy systems represents Invetech’s contribution to making life-saving therapies accessible to more patients at higher pace.”

Leveraging our years of experience, intellectual property and technical capability, we have developed ready-to-run turnkey systems to produce advanced cell therapy solutions at scale. In the upcoming weeks, we are bringing the first of these holistic, turnkey systems to market.

These new, ready-to-run systems will offer greater speed, efficiency, reliability and scalability in the advancement of life-saving therapies for our clients and the treatment of their patients.

Our ready-to-run systems reflect the thoughtful design and precision engineering that clients have come to expect from our custom solutions.

Invetech’s cell therapy systems offer: 

Efficiency

Available ready-to-run, our turnkey systems help reduce manufacturing costs and accelerate time to market.

Flexibility

Our systems offer modular options as well as customization capabilities, as needed. Designed as standalone systems for unit operations, our systems can be easily integrated into end-to-end production solutions.

Simplicity

We’ve put simplicity and automation at the top of the design agenda, reducing the clients’ burden on skilled operators.

Reliability

A holistic approach to design, engineering and manufacturing assures clients that the solutions are proficient for small and larger-scale production environments. Closed systems reduce the amount of user involvement/interruptions to process, reducing variability and increasing reliability.

We will continue to support our clients in the research, design, engineering and manufacture of custom cell therapy solutions alongside our new ready-to-run turnkey systems offering. Our continuous learning through further pioneering will continue to feed advancements in future turnkey system offerings.

Together, in partnership, we help our clients deliver the great potential of regenerative medicine products to patients faster.

Stay tuned for our first ready-to-run turnkey system launching in the upcoming weeks.

¹ Invetech’s ready-to-run turnkey systems may require minor configuration before sale and use depending on customer needs.

About Invetech

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. Through ready-to-run systems, custom solutions and full-spectrum services, we swiftly accelerate vital, emerging therapies from the clinic to commercial-scale manufacturing. Together with our partners, we expand the reach of next-generation medical advances that are revolutionizing healthcare.